Mineralys Therapeutics, Inc.
General ticker "MLYS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Mineralys Therapeutics, Inc. follows the US Stock Market performance with the rate: 42.3%.
Estimated limits based on current volatility of 2.2%: low 36.01$, high 37.65$
Factors to consider:
- Total employees count: 12 as of 2022
- Current price 102.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.14$, 17.77$]
- 2025-12-31 to 2026-12-31 estimated range: [5.83$, 14.87$]
Short-term MLYS quotes
Long-term MLYS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $31.48MM | $84.66MM | $192.40MM |
| Operating Income | $-31.48MM | $-84.66MM | $-192.40MM |
| Non-Operating Income | $1.68MM | $12.76MM | $14.59MM |
| Interest Expense | $1.68MM | $0.00MM | $0.00MM |
| R&D Expense | $26.25MM | $70.36MM | $168.58MM |
| Income(Loss) | $-29.80MM | $-71.90MM | $-177.81MM |
| Profit(Loss)* | $-29.80MM | $-71.90MM | $-177.81MM |
| Stockholders Equity | $-52.27MM | $241.15MM | $191.26MM |
| Assets | $114.44MM | $251.64MM | $205.90MM |
| Operating Cash Flow | $-29.22MM | $-81.17MM | $-166.31MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.10MM |
| Investing Cash Flow | $-21.76MM | $-160.47MM | $114.96MM |
| Financing Cash Flow | $128.02MM | $203.25MM | $116.14MM |
| Earnings Per Share** | $-5.77 | $-1.99 | $-3.66 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.